An early-stage technology that may revolutionize the way burn victims are treated is generating considerable buzz in Toronto media this week.
Globe and Mail reporter Robert Everett-Green wrote about the joint University of Toronto and Sunnybrook Health Sciences Centre project January 20 in "A 3-D machine that prints skin? How burn care could be revolutionized."
Health reporter Beatrice Politi also covered the Bio Printer project for Global News Toronto January 21. Her video segment includes an interview with PhD student Lian Leng and ...
MaRS Innovation's (MI) projects and partnerships earned three separate article mentions in the December 2012 issue of Biotechnology Focus, including:
MI and UHN's partnership with Stem Cell Therapeutics was covered in the magazine's Dealmakers subsection. Read the write-up on the Biotechnology Focus website.
Cellax, a licensable technology that may produce a nanotechonology-based cancer drug, was highlighted in the magazine's Business Corner section (read the write-up). Cellax is a joint project between MI and the Ontario Institute for Cancer Research.
MaRS Innovation's ...
Being named to the MIT Technology Review's 35 Inventors Under 35 list is a prestigious honour, but one of its best perks is the subsequent invitation to attend the Emerging Technologies conference (EmTech).
Joyce Poon and Hossein Rahnama, both researchers and inventors working with MaRS Innovation to license or spin-off technology projects, were named to the MIT Technology Review‘s prestigious 35 Inventors Under 35 list for 2012.
They attended the EmTech 2012 from October 24 to 26 where they each made a three-minute ...
Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), a life sciences company developing stem cell-related technologies, today announced the signing of an agreement with University Health Network (UHN), through its commercialization agent MaRS Innovation (MI), both of Toronto.
The agreement provides Stem Cell Therapeutics ("SCT") with an option to an exclusive world-wide license to an innovative cancer stem cell program.
This agreement produced a license for a UHN technology on April 17, 2013.
MaRS Innovation and York University’s commercialization office support new partnership
In the age of ITunes, videotaping lectures or converting existing textbooks into e-books won’t make you the market leader in online education.
Thanks to a new partnership between ClevrU, and NewMindsets Inc., facilitated by MaRS Innovation and York University’s commercialization office, Canadian technology and content promises to establish the second-generation online learning standard for millions of students worldwide. (more…)
The Los Angeles Times featured Dr. Gregory Czarnota's research in their Science Now section on July 10, 2012, which reports on discoveries from the world of science and medicine (update: the article is no longer available online).
Czarnota, a researcher at the Sunnybrook Health Sciences Centre, is working with MaRS Innovation to license his patented technology: radiosensitization of tumour cells using a combination of microbubbles and targeted, high-intensity, focused ultrasound. (more…)
Bridgewater, NJ and Toronto, ON- February 15, 2011 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Sunnybrook Health Sciences Centre (Toronto, Canada) announced that they have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds. This includes neuropathic diabetic foot ulcers caused by a lack of sensation and neuropathic ulcers that are complicated by peripheral arterial disease, commonly called neuroischemic diabetic foot ulcers.
“Our new relationship with Sunnybrook Health Sciences Centre fits our strategy ...
CAMH and MaRS Innovation partner on innovative approach to nicotine addiction
TORONTO (Dec. 17, 2009) — Grappling with nicotine addiction is never easy, but a new drug therapy – developed by Dr. Fang Liu at the Centre for Addiction and Mental Health (CAMH) – brings promise to one of our great public health challenges.
The experimental medication in development at Dr. Liu’s lab targets the brain chemistry associated with addiction by disrupting a specific receptor-receptor interaction.
Proof-of-concept data demonstrate that this therapy decreases addictive ...
TORONTO (June 30, 2009) – MaRS Innovation (MI) and the University of Toronto (U of T) are pleased to announce that they have entered into an agreement to collaboratively commercialize a novel sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers.
“There are 300 million diabetics worldwide, of which some 15 per cent develop troublesome foot ulcers. This wound healing technology is extremely exciting, making it an early commercialization opportunity that MaRS Innovation has identified as being a potential win for some ...